02 9487 9111

Sydney Adventist Hospital
« View pages

Clinical Specialties - Cancer

Bladder Cancer Clinical Trials


Adding Mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomized phase 3 trial "(BCG + MMC Trial)"


FORT-1 - Recruiting

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma


KEYNOTE 676 - Pending

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676



Back to Top

Sydney Adventist Hospital Clinical Specialties and Services